Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
7.60
+0.60 (8.57%)
Feb 11, 2025, 11:03 AM EST - Market open
Valneva SE Employees
Valneva SE had 676 employees as of December 31, 2023. The number of employees decreased by 43 or -5.98% compared to the previous year.
Employees
676
Change (1Y)
-43
Growth (1Y)
-5.98%
Revenue / Employee
$261,565
Profits / Employee
-$12,239
Market Cap
565.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
VALN News
- 6 days ago - Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ® - GlobeNewsWire
- 11 days ago - Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - GlobeNewsWire
- 18 days ago - Valneva Is A 'Buy' As A First-Mover In Chikungunya - Seeking Alpha
- 19 days ago - Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision - GlobeNewsWire
- 21 days ago - Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot - Benzinga
- 21 days ago - Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - GlobeNewsWire
- 5 weeks ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire